Sai Life Sciences Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/d979woduvpnwyp2vuhyezuqk.pdf

Key Takeaways


FTE Model Migration: The Core Structural Shift

Krishna Kanumuri: "If you look at the Wuxi model, the customers are engage across discovery, integrated discovery services. Then they're doing all the FTE development services and commercial manufacturing. What India has seen as a first phase is discovery chemistry services and then tech transfer at late-stage commercial manufacturing. But what we are seeing now is the middle part, which is FTE collaboration, with many of these relationships beginning to migrate here."

Capacity Build-Out and the H2 Bet

Siva Chittor: "There are times in history where even in Sai, where we have demonstrated that when we have seen capacity addition requirements slows down, we slow down the capex. And that is the only way to kind of control and be modular and be as just-in-time as possible as is needed for the business."

New Modalities: Peptides, ADCs, and the Platform Bet

Krishna Kanumuri: "We are not solely focused on just the GLP-1 space. We are taking a very big position built to support peptides across the therapeutic window. ... we are not just chasing a single modality, we are really building broad-based capabilities in peptides and built a significant technology platform for peptides."

CRO Momentum and Customer Depth

Krishna Kanumuri: "The expectation is for strong scientifically led partners who can take greater ownership of discovery and development programs rather than simply executing individual pieces of work."

Commercial Pipeline and Regulatory Catalysts


Guidance, Philosophy, and What Management Declined to Answer

Siva Chittor: "Have I put all my bets on it and every last dollar to get the 15%-20%? Obviously, we would also want to kind of make sure we will meet and beat guidance that we give to the market."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% to 20% over a three-to-five-year periodMid-term (3–5 years)
EBITDA margin28% to 30% rangeMid-term (3–5 years)
H2 stronger than H1Driven by capacity coming onlineEnd of Q2 or early Q3 FY27
Capacity targetReach 1,150 KL total capacityBy FY27
Bidar production block 1225 KL block completionH2 or Q3 FY27
Formulation capabilityClinical oral solids up to Phase 2 operationalApproximately six months (~Q3/Q4 FY27)
Peptide commercial facilityGround-breaking at greenfield site near Hyderabad; operational2028
Peptide total spendLess than INR 300 croresToward end of 2028
Large pharma FTE engagement (new)Negotiations to close; work to commenceClose by end of Q2 FY27; work from Q3 FY27
Integrated model conversionsTransition at least two large pharma customers to integrated modelsFY27
Regulatory milestonesTwo customer milestonesFY27
Regulatory milestone (additional)One customer milestoneQ2 FY28
AI initiative updateUpdate on AI-driven productivity initiativesBefore end of FY27

Key Metrics

MetricQ1 FY27
Revenue₹553 cr, +12% YoY vs ₹496 cr in Q1 FY26
CDMO revenue share~60% of total revenue
CRO revenue share~40% of total revenue
CRO revenue growth~26% YoY
CDMO revenue growth~6% YoY
Active commercial molecules33
Late-phase molecules14
Late-phase molecules added (last 15 months)6, of which 5 came through large pharma FTE engagements
Returning customer revenue shareOver 90% in FY25 and FY26
FDA-approved molecules contributed to (CY2025)5
Launches supported (past 5 years)17
Revenue growth guidance (mid-term)15% to 20% over a three-to-five-year period
EBITDA margin guidance28% to 30%
FY27 capex guidance₹1,100 cr to ₹1,300 cr
Capacity target1,150 KL by FY27